327 related articles for article (PubMed ID: 25702260)
1. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
[TBL] [Abstract][Full Text] [Related]
2. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
3. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
Wakatsuki T; Ishizuka N; Hironaka S; Minashi K; Kadowaki S; Goto M; Shoji H; Hirano H; Nakayama I; Osumi H; Ogura M; Chin K; Yamaguchi K; Takahari D
Int J Clin Oncol; 2024 Jun; 29(6):801-812. PubMed ID: 38589679
[TBL] [Abstract][Full Text] [Related]
4. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
Fornier MN; Seidman AD; Schwartz MK; Ghani F; Thiel R; Norton L; Hudis C
Ann Oncol; 2005 Feb; 16(2):234-9. PubMed ID: 15668276
[TBL] [Abstract][Full Text] [Related]
5. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum HER2-ECD levels in patients with gastric cancer.
Oyama K; Fushida S; Tsukada T; Kinoshita J; Watanabe T; Shoji M; Nakanuma S; Okamoto K; Sakai S; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Tajiri R; Ooi A; Ohta T
J Gastroenterol; 2015 Jan; 50(1):41-5. PubMed ID: 24557054
[TBL] [Abstract][Full Text] [Related]
7. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
8. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
[TBL] [Abstract][Full Text] [Related]
9. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
11. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
12. [A case of advanced gastric cancer in which the serum HER2-ECD level could be used as a biomarker].
Terakawa H; Oyama K; Watanabe T; Tsukada T; Okamoto K; Kinoshita J; Furukawa H; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Ohta T
Gan To Kagaku Ryoho; 2014 Apr; 41(4):491-3. PubMed ID: 24743367
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
14. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
16. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
[TBL] [Abstract][Full Text] [Related]
17. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
[TBL] [Abstract][Full Text] [Related]
18. Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer.
Ock CY; Lee KW; Kim JW; Kim JS; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Kim WH; Bang YJ; Oh DY
Clin Cancer Res; 2015 Jun; 21(11):2520-9. PubMed ID: 25712681
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
[TBL] [Abstract][Full Text] [Related]
20. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
